New structure for Singapore Health Sciences Authority
This article was originally published in Scrip
Singapore's Health Sciences Authority reorganised its structure at the beginning of the month in a move it said was designed to improve collaboration across the organisation. As a result of a review begun last year, three professional groups are responsible for health products regulation (including therapeutic products), blood services (formerly health services) and applied sciences. Comprising various operating divisions, these operate alongside a corporate headquarters under a CEO. The body is a statutory board of Singapore's ministry of health.
You may also be interested in...
Asia Deal Watch: RAPT And Hanmi Partner On CCR4 Antagonist Offering Potential In Multiple Cancer Types
RAPT can earn up to $108m in milestones plus sales royalties under the deal. BerGenBio, Piramal partner on developing AML therapy.
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?